TCRs Used in Cancer Gene Therapy Cross-React with MART-1/Melan-A Tumor Antigens via Distinct Mechanisms - Wikidata - wikimedia - TriplyDB

TCRs Used in Cancer Gene Therapy Cross-React with MART-1/Melan-A Tumor Antigens via Distinct Mechanisms

TCRs Used in Cancer Gene Therapy Cross-React with MART-1/Melan-A Tumor Antigens via Distinct Mechanisms

http://www.wikidata.org/entity/Q27671024

about

Identifying Individual T Cell Receptors of Optimal Avidity for Tumor Antigens Immunology in the clinic review series; focus on cancer: double trouble for tumours: bi-functional and redirected T cells as effective cancer immunotherapies Minimal conformational plasticity enables TCR cross-reactivity to different MHC class II heterodimers Loss of T Cell Antigen Recognition Arising from Changes in Peptide and Major Histocompatibility Complex Protein Flexibility: IMPLICATIONS FOR VACCINE DESIGN T-cell Receptor Specificity Maintained by Altered Thermodynamics Increased peptide contacts govern high affinity binding of a modified TCR whilst maintaining a native pMHC docking mode Disparate Epitopes Mediating Protective Heterologous Immunity to Unrelated Viruses Share Peptide-MHC Structural Features Recognized by Cross-Reactive T Cells Crossreactivity of a human autoimmune TCR is dominated by a single TCR loop Computational Design of the Affinity and Specificity of a Therapeutic T Cell Receptor Effect of CDR3 Sequences and Distal V Gene Residues in Regulating TCR-MHC Contacts and Ligand Specificity TCR affinity for p/MHC formed by tumor antigens that are self-proteins: impact on efficacy and toxicity Reconciling views on T cell receptor germline bias for MHC How (specific) would like your T-cells today? Generating T-cell therapeutic function through TCR-gene transfer T cell receptor bias for MHC: co-evolution or co-receptors?Peptide modulation of class I major histocompatibility complex protein molecular flexibility and the implications for immune recognition.How structural adaptability exists alongside HLA-A2 bias in the human αβ TCR repertoire T cell avidity and tumor immunity: problems and solutions Cutting edge: Evidence for a dynamically driven T cell signaling mechanism.The basis for limited specificity and MHC restriction in a T cell receptor interface.Specific increase in potency via structure-based design of a TCR.Plasticity in the contribution of T cell receptor variable region residues to binding of peptide-HLA-A2 complexes.Soluble T-cell receptors produced in human cells for targeted delivery.Structure of Staphylococcal Enterotoxin E in Complex with TCR Defines the Role of TCR Loop Positioning in Superantigen Recognition.Structural interplay between germline interactions and adaptive recognition determines the bandwidth of TCR-peptide-MHC cross-reactivity.Targeting human melanoma neoantigens by T cell receptor gene therapy T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy Differential utilization of binding loop flexibility in T cell receptor ligand selection and cross-reactivity.Hotspot autoimmune T cell receptor binding underlies pathogen and insulin peptide cross-reactivity.Comparison of cytotoxic T lymphocyte responses against pancreatic cancer induced by dendritic cells transfected with total tumor RNA and fusion hybrided with tumor cell.An Engineered Switch in T Cell Receptor Specificity Leads to an Unusual but Functional Binding Geometry.Role of T cell receptor affinity in the efficacy and specificity of adoptive T cell therapies.TCR scanning of peptide/MHC through complementary matching of receptor and ligand molecular flexibility.Structural and dynamic control of T-cell receptor specificity, cross-reactivity, and binding mechanism.A structural voyage toward an understanding of the MHC-I-restricted immune response: lessons learned and much to be learned.Understanding the complexity and malleability of T-cell recognition.Conserved Vδ1 binding geometry in a setting of locus-disparate pHLA recognition by δ/αβTCRs: insight into recognition of HIV peptides by TCR.CD8 T-cell responses against the immunodominant Theileria parva peptide Tp249-59 are composed of two distinct populations specific for overlapping 11-mer and 10-mer epitopes.Driving gene-engineered T cell immunotherapy of cancer.Role of the MHC restriction during maturation of antigen-specific human T cells in the thymus.Lipopeptides: a novel antigen repertoire presented by major histocompatibility complex class I molecules.

P2860

Q26774669-24F3972C-C8F9-40A3-AA00-AF88C07F796C Q27027243-33AB6686-12AB-4503-924A-8E5B36949A09 Q27672472-65089265-EB67-4077-B81E-882FEA49DE2E Q27674375-2CD9962C-C84C-4BD6-AD25-AB8406265929 Q27678265-C104EA7C-514C-4DF7-9E0D-C767B3F9E6E0 Q27678823-0C861358-3DC9-4BD6-A41A-EFFE91E9DC64 Q27680365-93AB20A0-0D11-46D1-9A6D-405F8A59669D Q27680393-3040275F-F108-4576-AF59-DEC84729C5DC Q27681832-1819C500-2666-454D-AFC9-C68618BF45EF Q27683690-4C9E347F-2B5C-43B2-AAE5-6FF7AD95932D Q28081699-9C739411-03D5-4389-8F74-E26BBC32AE1B Q28270580-5867A92F-2C62-4328-9CC5-7F2BD12E7392 Q28727481-C73E30DD-B039-4D5A-8033-FF1EABA874E9 Q29037684-5D0E1262-F8C6-426B-9628-893E22B28F49 Q30351955-E49FCC21-37E0-4BF8-A0FB-275A696B47A5 Q33362590-0DD422C2-D7D4-415C-A936-65A9798D518B Q34115960-3FA0D849-09B0-47D8-92D3-E78484EE2D47 Q34275752-5D346A63-B27A-4446-9006-1F835A5DDD3D Q34348673-43D0E616-A3A2-479E-9227-2AF0900E0EA1 Q34383054-70BD765C-5BEC-4553-B929-6A132F2FD6F4 Q34953926-EE5CDFD7-387E-415E-8D21-3FADC263E6C7 Q35602230-DDC287BF-DAEE-4170-B810-87D1F5BAE4E0 Q35683701-BF13972B-D25E-46D3-956E-4B73C0AB6121 Q36386316-45735110-C870-4FD0-B495-EC2F4C0E5E1B Q36618620-9CA06144-3642-4CED-97D5-5C9AD2ECCDC1 Q36799229-3630E3F3-28A1-4CA5-AD29-0806A0E62840 Q36841051-86EF6CB5-95C7-4621-9E8C-8CD24DDF7923 Q36951745-BD04BC10-490D-4C19-80A8-6065712B1417 Q37071139-79DB4500-DBF4-4561-95F9-529DDD762BBB Q37079836-851A8B51-FAB3-4D59-A6E4-94272AE5D834 Q37107843-C66238C4-3C69-44C1-9E14-985FBF529437 Q37711339-96BDAD07-3230-4563-A7C6-DB9311DA4681 Q38050477-76319C89-966D-4C92-8E58-C6C63E123A7C Q38050479-853FB8A1-AD2E-4318-AB00-E956E7DB6C31 Q38315875-B2234248-C0BB-4037-9836-F865437265A8 Q38725477-7183AEEC-E031-4A27-AE18-C7C20057E28F Q38763675-FD064138-8528-404F-ADB5-D6314594910A Q38777742-CEA79532-6FD9-43F4-83D5-EEA9A539540E Q38814475-2665C9BA-D361-4FE0-96C0-4BD2AA016030 Q38893422-08CA6A75-BA47-430E-85A9-249690308E91

P2860

TCRs Used in Cancer Gene Therapy Cross-React with MART-1/Melan-A Tumor Antigens via Distinct Mechanisms

http://www.wikidata.org/entity/Q27671024

description

2011 nî lūn-bûn

@nan

2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

TCRs Used in Cancer Gene Thera ...... tigens via Distinct Mechanisms

@ast

TCRs Used in Cancer Gene Thera ...... tigens via Distinct Mechanisms

@en

TCRs Used in Cancer Gene Thera ...... tigens via Distinct Mechanisms

@nl

type

label

TCRs Used in Cancer Gene Thera ...... tigens via Distinct Mechanisms

@ast

TCRs Used in Cancer Gene Thera ...... tigens via Distinct Mechanisms

@en

TCRs Used in Cancer Gene Thera ...... tigens via Distinct Mechanisms

@nl

prefLabel

TCRs Used in Cancer Gene Thera ...... tigens via Distinct Mechanisms

@ast

TCRs Used in Cancer Gene Thera ...... tigens via Distinct Mechanisms

@en

TCRs Used in Cancer Gene Thera ...... tigens via Distinct Mechanisms

@nl

P1433

Q27671024-B3A2F8BF-C243-4C70-86F1-53295D7EB8E3

P1476

Q27671024-DA812EE4-EDEF-45C8-AF59-9973842EBD90

P2093

Q27671024-6E6CA021-BA54-4899-B4E7-345F08E1B4E5

Q27671024-C403ED8A-948C-4C39-9CC4-66DC21C76076

Q27671024-D30B85B5-49FA-467E-89D6-C4727D7577AA

Q27671024-F723D832-4115-483F-BBF7-499F8860D627

P2860

Q27671024-0CD646BE-E4FA-435F-B22C-FA7F5B2BE39C

Q27671024-0FE89906-2CDE-4D4A-8EC6-7D9D867E2E54

Q27671024-10399C5A-5DBB-482D-95A4-EDAF153F6716

Q27671024-158DCAE1-4EE9-4384-9994-AFD1E34DCB80

Q27671024-16BC3C8E-3EA0-4E05-8BCC-78900DE291C6

Q27671024-2771159D-A5BD-49A8-93B8-5C6EF09F80A2

Q27671024-29F34101-8DF1-4EE5-A221-5BB5ADAF381B

Q27671024-2AD2E991-93CE-4F25-8C91-A89FBF23991B

Q27671024-2B3D1507-1063-4BA8-BA4D-D77648C06CFD

Q27671024-2D3FA5AD-6D30-4925-AA00-295FAD45B1CA

P304

Q27671024-E6C048E5-4667-4333-AF7D-D9C31B10B8AE

P31

Q27671024-007BC5E4-C95A-4D0D-94E2-81910598A592

P3181

Q27671024-44ED6EDD-8DE7-423E-8CFC-1C5B0E77D985

P356

Q27671024-28F2230F-C965-4F64-93E1-3E7287C516BD

P407

Q27671024-9DACCBC3-6ED8-45B2-A07D-DD805A050372

P433

Q27671024-0EE6BD77-4CD5-453A-89A8-F732BE1199A4

P478

Q27671024-BB118D98-748F-4E2F-A380-214D7F8B32C3

P577

Q27671024-F5DD933B-8C9B-4DE3-8E9F-E57F62A1423E

P5875

Q27671024-848E7BF7-B55C-4610-96F8-7401BE388A1B

P698

Q27671024-6421D39B-1CFE-4F67-8092-034C59135F72

P921

Q27671024-61506B94-FEB2-4693-9233-6C0C2ADC227E

P932

Q27671024-6B408B13-A267-48C8-8B40-53DCA772C63D

P3181

P356

JIMMUNOL.1101268

P1433

Journal of Immunology

P1476

TCRs Used in Cancer Gene Thera ...... tigens via Distinct Mechanisms

@en

P2093

Brian M Baker

http://www.w3.org/2001/XMLSchema#string

Moushumi Hossain

http://www.w3.org/2001/XMLSchema#string

Oleg Y Borbulevych

http://www.w3.org/2001/XMLSchema#string

Sujatha M Santhanagopolan

http://www.w3.org/2001/XMLSchema#string

P2860

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

MolProbity: all-atom structure validation for macromolecular crystallography

Cancer regression in patients after transfer of genetically engineered lymphocytes

Crystal structures of two closely related but antigenically distinct HLA-A2/melanocyte-melanoma tumor-antigen peptide complexes

A T cell receptor flattens a bulged antigenic peptide presented by a major histocompatibility complex class I molecule

How a single T cell receptor recognizes both self and foreign MHC

Structural evidence for a germline-encoded T cell receptor-major histocompatibility complex interaction 'codon'

Structures of MART-126/27–35 Peptide/HLA-A2 Complexes Reveal a Remarkable Disconnect between Antigen Structural Homology and T Cell Recognition

Germ Line-governed Recognition of a Cancer Epitope by an Immunodominant Human T-cell Receptor

P304

2453-63

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1618328

http://www.w3.org/2001/XMLSchema#string

P356

10.4049/JIMMUNOL.1101268

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

187

http://www.w3.org/2001/XMLSchema#string

P577

2011-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51527159

http://www.w3.org/2001/XMLSchema#string

P698

21795600

http://www.w3.org/2001/XMLSchema#string

P921

P932

3166883

http://www.w3.org/2001/XMLSchema#string